HC Wainwright Issues Pessimistic Estimate for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Research analysts at HC Wainwright decreased their Q1 2025 earnings per share (EPS) estimates for Greenwich LifeSciences in a research report issued on Monday, April 21st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.24) for the quarter, down from their previous forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS and FY2025 earnings at ($0.94) EPS.

Greenwich LifeSciences (NASDAQ:GLSI) last posted its earnings results on Tuesday, April 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.40).

Greenwich LifeSciences Stock Up 2.3 %

NASDAQ:GLSI opened at $9.85 on Wednesday. Greenwich LifeSciences has a twelve month low of $8.06 and a twelve month high of $18.75. The stock has a market cap of $130.75 million, a P/E ratio of -12.31 and a beta of 1.76. The firm’s fifty day simple moving average is $10.71 and its 200 day simple moving average is $12.29.

Insider Activity

In other news, CEO Snehal Patel bought 5,500 shares of the stock in a transaction dated Friday, April 4th. The stock was bought at an average price of $8.73 per share, for a total transaction of $48,015.00. Following the purchase, the chief executive officer now directly owns 5,558,002 shares in the company, valued at $48,521,357.46. This trade represents a 0.10 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have purchased 14,500 shares of company stock valued at $129,267. Corporate insiders own 51.67% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors have recently added to or reduced their stakes in the company. Garden State Investment Advisory Services LLC bought a new position in shares of Greenwich LifeSciences in the 3rd quarter worth about $253,000. Northern Trust Corp grew its holdings in Greenwich LifeSciences by 17.3% in the fourth quarter. Northern Trust Corp now owns 87,423 shares of the company’s stock worth $982,000 after purchasing an additional 12,923 shares during the period. Barclays PLC increased its stake in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company’s stock valued at $1,919,000 after purchasing an additional 5,861 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Greenwich LifeSciences by 172.0% during the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock valued at $79,000 after purchasing an additional 4,465 shares during the last quarter. Institutional investors own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.